IBRX Q1 2024 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40,000-88.9% YoY

Gross Profit

$40,000100.0% margin

Operating Income

-$95M-237990.0% margin

Net Income

-$134M-335272.5% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-71.2%

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$108M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$401M

Total Liabilities

$1.1B

Stockholders' Equity

-$692M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40,000	$360,000	-88.9%
Gross Profit	$40,000	-$6M	+100.7%
Operating Income	-$95M	-$112M	+14.7%
Net Income	-$134M	-$116M	-15.3%